We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson and Company (BDX - Free Report) , also popularly known as BD, recently launched BD PurPrep patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation commercially available in the United States.
This is expected to boost the company’s Life Sciences segment.
BD PurPrep at a Glance
The new BD PurPrep formulation comprises of a fluid-resistant, film-forming polymer designed to facilitate drape adhesion and help create a durable anti-microbial barrier that helps iodine bind to the skin for residual antimicrobial activity. In an irrigation study emulating real-world clinical practice, BD PurPrep patient preoperative skin preparation with sterile solution stayed on the skin immediately following a saline challenge.
More About BD PurPrep
Other than BD ChloraPrep patient preoperative skin preparation, BD PurPrep is the first and only fully sterile skin preparation available that utilizes a single-use applicator specifically designed to curb cross-contamination and promote aseptic non-touch technique. The BD PurPrep patient preoperative skin preparation is an effective skin preparation option when the use of a chlorhexidine gluconate is contra-indicated or the patient is sensitive to CHG.
By developing fully sterile PurPrep and ChloraPrep, BD is offering healthcare experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
By adding a non-CHG, fully sterile skin preparation option, BD is broadening the availability of tools to help mitigate the risk of infection in patients with CHG sensitivities and during procedures where CHG/IPA is not indicated.
Notably, the new BD PurPrep sterile solution will include a mark to indicate that the solution is sterile. Though not required by the FDA, BD developed this mark to differentiate sterile solutions from non-sterile antiseptic skin preparations. Also, BD PurPrep will replace Prevail and Prevail FX, and is available now through BD and other distribution partners.
Other Developments
In February 2020, the company announced that BD Synapsys microbiology informatics solution, the company’s integrated diagnostics informatics platform, has been authorized by the Underwriters Laboratory Cybersecurity Assurance Program. This independent program utilizes standardized, testable criteria for evaluating software vulnerabilities and weaknesses.
Around the same time, the company announced that the BD Kiestra ReadA is device listed with the FDA. The BD Kiestra ReadA, which is available as a standalone instrument, helps enhance operational efficiency in clinical microbiology laboratories by automating routine plate-management tasks and offering proficiency through standardized digital image acquisition.
Market Prospects
Per a report by Grand View Research, the global infection control market size was estimated at $150.4 billion in 2016 and is anticipated to grow at a CAGR of 6.2% throughout the forecast period of 2018-2025. Hence, this launch is well-timed.
Price Performance
Over the past year, the stock has lost 0.1% compared with the 11.8% decline of its industry.
Zacks Rank and Key Picks
BD currently has a Zacks Rank#3 (Hold).
A few better-ranked stocks from the broader medical space include Laboratory Corporation of America Holdings (LH - Free Report) , Surmodics (SRDX - Free Report) and Quest Diagnostics (DGX - Free Report) .
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).
Quest Diagnostics’ long-term earnings growth rate is estimated at 7.6%. It currently carries a Zacks Rank #1.
5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
Image: Bigstock
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
Becton, Dickinson and Company (BDX - Free Report) , also popularly known as BD, recently launched BD PurPrep patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation commercially available in the United States.
This is expected to boost the company’s Life Sciences segment.
BD PurPrep at a Glance
The new BD PurPrep formulation comprises of a fluid-resistant, film-forming polymer designed to facilitate drape adhesion and help create a durable anti-microbial barrier that helps iodine bind to the skin for residual antimicrobial activity. In an irrigation study emulating real-world clinical practice, BD PurPrep patient preoperative skin preparation with sterile solution stayed on the skin immediately following a saline challenge.
More About BD PurPrep
Other than BD ChloraPrep patient preoperative skin preparation, BD PurPrep is the first and only fully sterile skin preparation available that utilizes a single-use applicator specifically designed to curb cross-contamination and promote aseptic non-touch technique. The BD PurPrep patient preoperative skin preparation is an effective skin preparation option when the use of a chlorhexidine gluconate is contra-indicated or the patient is sensitive to CHG.
By developing fully sterile PurPrep and ChloraPrep, BD is offering healthcare experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
By adding a non-CHG, fully sterile skin preparation option, BD is broadening the availability of tools to help mitigate the risk of infection in patients with CHG sensitivities and during procedures where CHG/IPA is not indicated.
Notably, the new BD PurPrep sterile solution will include a mark to indicate that the solution is sterile. Though not required by the FDA, BD developed this mark to differentiate sterile solutions from non-sterile antiseptic skin preparations. Also, BD PurPrep will replace Prevail and Prevail FX, and is available now through BD and other distribution partners.
Other Developments
In February 2020, the company announced that BD Synapsys microbiology informatics solution, the company’s integrated diagnostics informatics platform, has been authorized by the Underwriters Laboratory Cybersecurity Assurance Program. This independent program utilizes standardized, testable criteria for evaluating software vulnerabilities and weaknesses.
Around the same time, the company announced that the BD Kiestra ReadA is device listed with the FDA. The BD Kiestra ReadA, which is available as a standalone instrument, helps enhance operational efficiency in clinical microbiology laboratories by automating routine plate-management tasks and offering proficiency through standardized digital image acquisition.
Market Prospects
Per a report by Grand View Research, the global infection control market size was estimated at $150.4 billion in 2016 and is anticipated to grow at a CAGR of 6.2% throughout the forecast period of 2018-2025. Hence, this launch is well-timed.
Price Performance
Over the past year, the stock has lost 0.1% compared with the 11.8% decline of its industry.
Zacks Rank and Key Picks
BD currently has a Zacks Rank#3 (Hold).
A few better-ranked stocks from the broader medical space include Laboratory Corporation of America Holdings (LH - Free Report) , Surmodics (SRDX - Free Report) and Quest Diagnostics (DGX - Free Report) .
LabCorp’s long-term earnings growth rate is estimated at 6.1%. The company presently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).
Quest Diagnostics’ long-term earnings growth rate is estimated at 7.6%. It currently carries a Zacks Rank #1.
5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
See the 5 high-tech stocks now>>